tbuckley/cabot-search huggingface dataset:
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Authors: Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes
Journal: Blood (2024)

Abstract Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL) requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly benefit individuals with MBL. Patients with CLL separate into 3 distinct epigenetic subtypes (epitypes) with high prognostic significance, and recently the intermediate epitype has been shown to be enriched for high-risk immunoglobulin lambda variable (IGLV) 3-21 rearrangements, impacting outcomes for these patients. Here, we employed this combined strategy to generate the epigenetic and light chain immunoglobulin (ELCLV3-21) signature to classify 219 individuals with MBL. The ELCLV3-21 high-risk signature distinguished MBL individuals with a high probability of progression (39.9% and 71.1% at 5 and 10 years, respectively). ELCLV3-21 improved the accuracy of predicting time to therapy for individuals with MBL compared with other established prognostic indicators, including the CLL international prognostic index (c-statistic, 0.767 vs 0.668, respectively). Comparing ELCLV3-21 risk groups in MBL vs a cohort of 226 patients with CLL revealed ELCLV3-21 high-risk individuals with MBL had significantly shorter time to therapy (P = .003) and reduced overall survival (P = .03) compared with ELCLV3-21 low-risk individuals with CLL. These results highlight the power of the ELCLV3-21 approach to identify individuals with a higher likelihood of adverse clinical outcome and may provide a more accurate approach to classify individuals with small B-cell clones.
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Authors: Andras Heczey, Xin Xu, Amy N. Courtney, Gengwen Tian, Gabriel A. Barragan, Linjie Guo, Claudia Martinez Amador, Nisha Ghatwai, Purva Rathi, Michael S. Wood, Yanchuan Li, Chunchao Zhang, Thorsten Demberg, Erica J. Di Pierro, Andrew C. Sher, Huimin Zhang, Birju Mehta, Sachin G. Thakkar, Bambi Grilley, Tao Wang, Brian D. Weiss, Antonino Montalbano, Meena Subramaniam, Chenling Xu, Chirag Sachar, Daniel K. Wells, Gianpietro Dotti, Leonid S. Metelitsa
Journal: Nature Medicine (2024)
Short-Stay Units vs Routine Admission From the Emergency Department in Patients With Acute Heart Failure
Authors: Peter S. Pang, David A. Berger, Simon A. Mahler, Xiaochun Li, Susan J. Pressler, Kathleen A. Lane, Jason J. Bischof, Douglas Char, Deborah Diercks, Alan E. Jones, Erik P. Hess, Phillip Levy, Joseph B. Miller, Arvind Venkat, Nicholas E. Harrison, Sean P. Collins
Journal: JAMA Network Open (2024)

Importance More than 80% of patients who present to the emergency department (ED) with acute heart failure (AHF) are hospitalized. With more than 1 million annual hospitalizations for AHF in the US, safe and effective alternatives are needed. Care for AHF in short-stay units (SSUs) may be safe and more efficient than hospitalization, especially for lower-risk patients, but randomized clinical trial data are lacking. Objective To compare the effectiveness of SSU care vs hospitalization in lower-risk patients with AHF. Design, Setting, and Participants This multicenter randomized clinical trial randomly assigned low-risk patients with AHF 1:1 to SSU or hospital admission from the ED. Patients received follow-up at 30 and 90 days post discharge. The study began December 6, 2017, and was completed on July 22, 2021. The data were analyzed between March 27, 2020, and November 11, 2023. Intervention Randomized post-ED disposition to less than 24 hours of SSU care vs hospitalization. Main Outcomes and Measures The study was designed to detect at least 1-day superiority for a primary outcome of days alive and out of hospital (DAOOH) at 30-day follow-up for 534 participants, with an allowance of 10% participant attrition. Due to the COVID-19 pandemic, enrollment was truncated at 194 participants. Before unmasking, the primary outcome was changed from DAOOH to an outcome with adequate statistical power: quality of life as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12). The KCCQ-12 scores range from 0 to 100, with higher scores indicating better quality of life. Results Of the 193 patients enrolled (1 was found ineligible after randomization), the mean (SD) age was 64.8 (14.8) years, 79 (40.9%) were women, and 114 (59.1%) were men. Baseline characteristics were balanced between arms. The mean (SD) KCCQ-12 summary score between the SSU and hospitalization arms at 30 days was 51.3 (25.7) vs 45.8 (23.8) points, respectively ( P = .19). Participants in the SSU arm had 1.6 more DAOOH at 30-day follow-up than those in the hospitalization arm (median [IQR], 26.9 [24.4-28.8] vs 25.4 [22.0-27.7] days; P = .02). Adverse events were uncommon and similar in both arms. Conclusions and Relevance The findings show that the SSU strategy was no different than hospitalization with regard to KCCQ-12 score, superior for more DAOOH, and safe for lower-risk patients with AHF. These findings of lower health care utilization with the SSU strategy need to be definitively tested in an adequately powered study. Trial Registration ClinicalTrials.gov Identifier: NCT03302910
Computational prediction and experimental validation identify functionally conserved lncRNAs from zebrafish to human
Authors: Wenze Huang, Tuanlin Xiong, Yuting Zhao, Jian Heng, Ge Han, Pengfei Wang, Zhihua Zhao, Ming Shi, Juan Li, Jiazhen Wang, Yixia Wu, Feng Liu, Jianzhong Jeff Xi, Yangming Wang, Qiangfeng Cliff Zhang
Journal: Nature Genetics (2024)

Abstract Functional studies of long noncoding RNAs (lncRNAs) have been hindered by the lack of methods to assess their evolution. Here we present lncRNA Homology Explorer (lncHOME), a computational pipeline that identifies a unique class of long noncoding RNAs (lncRNAs) with conserved genomic locations and patterns of RNA-binding protein (RBP) binding sites (coPARSE-lncRNAs). Remarkably, several hundred human coPARSE-lncRNAs can be evolutionarily traced to zebrafish. Using CRISPR–Cas12a knockout and rescue assays, we found that knocking out many human coPARSE-lncRNAs led to cell proliferation defects, which were subsequently rescued by predicted zebrafish homologs. Knocking down coPARSE-lncRNAs in zebrafish embryos caused severe developmental delays that were rescued by human homologs. Furthermore, we verified that human, mouse and zebrafish coPARSE-lncRNA homologs tend to bind similar RBPs with their conserved functions relying on specific RBP-binding sites. Overall, our study demonstrates a comprehensive approach for studying the functional conservation of lncRNAs and implicates numerous lncRNAs in regulating vertebrate physiology.
First-hit <i>SETBP1</i> mutations cause a myeloproliferative disorder with bone marrow fibrosis
Authors: Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini, Deborah D’Aliberti, Mario Mauri, Carl Mirko Mercado, Diletta Fontana, Silvia Spinelli, Valentina Crippa, Elena Inzoli, Beatrice Manghisi, Ivan Civettini, Daniele Ramazzotti, Valentina Sangiorgio, Michele Gengotti, Virginia Brambilla, Andrea Aroldi, Federica Banfi, Cristiana Barone, Roberto Orsenigo, Ludovica Riera, Mara Riminucci, Alessandro Corsi, Massimo Breccia, Alessandro Morotti, Daniela Cilloni, Aldo Roccaro, Antonio Sacco, Fabio Stagno, Marta Serafini, Federica Mottadelli, Giovanni Cazzaniga, Fabio Pagni, Roberto Chiarle, Emanuele Azzoni, Alessandro Sessa, Carlo Gambacorti-Passerini, Elena Maria Elli, Luca Mologni, Rocco Piazza
Journal: Blood (2024)
Paracrine signalling by pancreatic δ cells determines the glycaemic set point in mice
Authors: Jessica L. Huang, Mohammad S. Pourhosseinzadeh, Sharon Lee, Niels Krämer, Jaresley V. Guillen, Naomi H. Cinque, Paola Aniceto, Ariana T. Momen, Shinichiro Koike, Mark O. Huising
Journal: Nature Metabolism (2024)
The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies
Authors: Johanna B Tonko, Pier D Lambiase
Journal: Cardiovascular Research (2024)

Abstract Ventricular arrhythmias in cardiac channelopathies are linked to autonomic triggers, which are sub-optimally targeted in current management strategies. Improved molecular understanding of cardiac channelopathies and cellular autonomic signalling could refine autonomic therapies to target the specific signalling pathways relevant to the specific aetiologies as well as the central nervous system centres involved in the cardiac autonomic regulation. This review summarizes key anatomical and physiological aspects of the cardiac autonomic nervous system and its impact on ventricular arrhythmias in primary inherited arrhythmia syndromes. Proarrhythmogenic autonomic effects and potential therapeutic targets in defined conditions including the Brugada syndrome, early repolarization syndrome, long QT syndrome, and catecholaminergic polymorphic ventricular tachycardia will be examined. Pharmacological and interventional neuromodulation options for these cardiac channelopathies are discussed. Promising new targets for cardiac neuromodulation include inhibitory and excitatory G-protein coupled receptors, neuropeptides, chemorepellents/attractants as well as the vagal and sympathetic nuclei in the central nervous system. Novel therapeutic strategies utilizing invasive and non-invasive deep brain/brain stem stimulation as well as the rapidly growing field of chemo-, opto-, or sonogenetics allowing cell-specific targeting to reduce ventricular arrhythmias are presented.
Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer
Authors: Deborah Cosentini, Rebecca Pedersini, Pierluigi Di Mauro, Manuel Zamparini, Greta Schivardi, Luca Rinaudo, Nunzia Di Meo, Andrea Delbarba, Carlo Cappelli, Marta Laganà, Andrea Alberti, Maria Baronchelli, Greta Guerci, Lara Laini, Salvatore Grisanti, Edda Lucia Simoncini, Davide Farina, Gherardo Mazziotti, Alfredo Berruti, Monica Boglioni, Giulia Calzoni
Journal: JAMA Network Open (2024)

Importance Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and denosumab have not been explored to date. Objectives To evaluate whether an association exists between dual x-ray absorptiometry (DXA)–measured fat body mass (FBM) and vertebral fracture (VF) progression in postmenopausal women with EBC undergoing adjuvant therapy with AIs in combination with denosumab and to examine whether VF was associated with common risk factors for bone fracture and parameters of body composition other than FBM. Design, Setting, and Participants For this prospective, single-center, cohort study, 237 patients with EBC who were undergoing adjuvant treatment with AIs and denosumab (60 mg every 6 months) were enrolled at the Breast Unit of the ASST Spedali Civili of Brescia from September 2014 to June 2018. Data analysis was conducted in June 2022. Exposure Body composition parameters, bone mineral density, and morphometric VFs were assessed by DXA at study entry and after 18 months of therapy. Main Outcomes and Measures VF progression, defined as either new or worsening of preexisting VFs, between the 2 time points. Results Of the 237 patients enrolled (median [range] age, 61 [28-84] years), 17 (4.4%) reported VF progression. Univariable analysis found an association between VF progression and a history of clinical fractures (odds ratio [OR], 3.22; 95% CI, 1.19-8.74; P = .02), Fracture Risk Assessment Tool (FRAX) score for major fractures (OR, 4.42; 95% CI, 1.23-13.79; P = .04), percentage of FBM (OR, 6.04; 95% CI, 1.69-21.63; P = .006), and android fat (OR, 9.58; 95% CI, 1.17-78.21; P = .04) and an inverse association with appendicular lean mass index–FBM ratio (OR, 0.25, 95% CI, 0.08-0.82; P = .02). Multivariable analysis revealed percentage of FBM (OR, 5.41; 95% CI, 1.49-19.59; P = .01) and FRAX score (OR, 3.95; 95% CI, 1.09-14.39; P = .04) as independent variables associated with VF progression. Conclusions and Relevance The findings of this study suggest that baseline FBM is an independent factor for VF progression in patients with EBC treated with adjuvant AIs and denosumab. This observation is new and indicates that diet and exercise may synergize with denosumab in the management of bone health in this patient setting.
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Authors: Shubham Pant, Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, Olca Basturk, Haley VanWyk, Amy M. Tavares, Lochana M. Seenappa, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Eileen M. O’Reilly
Journal: Nature Medicine (2024)

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic and five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum tumor antigen) after locoregional treatment in a phase 1 study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909; study enrollment is complete with patient follow-up ongoing. Primary endpoints included safety and recommended phase 2 dose (RP2D). The secondary endpoint was tumor biomarker response (longitudinal ctDNA or tumor antigen), with exploratory endpoints including immunogenicity and relapse-free survival (RFS). No dose-limiting toxicities were observed, and the RP2D was 10.0 mg of Amph-CpG-7909. Direct ex vivo mKRAS-specific T cell responses were observed in 21 of 25 patients (84%; 59% both CD4
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells
Authors: Dhiraj Kumar, Sreeharsha Gurrapu, Yan Wang, Seong-Yeon Bae, Poonam R. Pandey, Hong Chen, Jayanta Mondal, Hyunho Han, Chang-Jiun Wu, Spyros Karaiskos, Fei Yang, Aysegul Sahin, Ignacio I. Wistuba, Jianjun Gao, Debasish Tripathy, Hua Gao, Benjamin Izar, Filippo G. Giancotti
Journal: Nature Cancer (2024)
Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma
Authors: Bangdong Liu, Xianlan Zhao, Shihao Zhang, Qiong Li, Xinlei Li, Dezhi Huang, Jing Xia, Naya Ma, Yishuo Duan, Xi Zhang, Jun Rao
Journal: Leukemia (2024)

Abstract S-palmitoylation is essential for cancer development via regulating protein stability, function and subcellular location, yet the roles S-palmitoylation plays in diffuse large B-cell lymphoma (DLBCL) progression remain enigmatic. In this study, we uncovered a novel function of the palmitoyltransferase ZDHHC21 as a tumor suppressor in DLBCL and identified ZDHHC21 as a key regulator of fatty acid synthetase (FASN) S-palmitoylation for the first time. Specifically, ZDHHC21 was downregulated in DLBCL, and its expression level was associated with the clinical prognosis of patients with DLBCL. In vitro and in vivo experiments suggested that ZDHHC21 suppressed DLBCL cell proliferation. Mechanistically, ZDHHC21 interacted with FASN and mediated its palmitoylation at Cys1317, resulting in a decrease in FASN protein stability and fatty acid synthesis, consequently leading to the inhibition of DLBCL cell growth. Of note, an FDA-approved small-molecule compound lanatoside C interacted with ZDHHC21, increased ZDHHC21 protein stability and decreased FASN expression, which contributed to the suppression of DLBCL growth in vitro and in vivo. Our results demonstrate that ZDHHC21 strongly represses DLBCL cell proliferation by mediating FASN palmitoylation, and suggest that targeting ZDHHC21/FASN axis is a potential therapeutic strategy against DLBCL.
Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial
Authors: Ran Cheng, Nadine Taleb, Zekai Wu, Delphine Bouchard, Valérie Parent, Marie-Laure Lalanne-Mistrih, Valérie Boudreau, Virginie Messier, Marie-Josée Lacombe, Caroline Grou, Anne-Sophie Brazeau, Rémi Rabasa-Lhoret
Journal: Diabetes Care (2024)

OBJECTIVE Current guidelines recommend initiating treatment for nonsevere (NS) hypoglycemia with 15 g carbohydrates (CHO) at 15-min intervals when blood glucose (BG) reaches &amp;lt;70 mg/dL (3.9 mmol/L). Despite this recommendation, NS hypoglycemia management remains challenging for individuals living with type 1 diabetes (T1D). We aimed to assess the efficacy of 15 g CHO at higher BG levels. RESEARCH DESIGN AND METHODS A total of 29 individuals with T1D participated in an open-label crossover study. After an inpatient subcutaneous insulin-induced decrease in BG in the fasting state, 16 g CHO was administered orally at a plasma glucose (PG) of &amp;lt;70 (3.9), ≤80 (4.5), or ≤90 mg/dL (5.0 mmol/L). The primary outcome was time spent in hypoglycemia (&amp;lt;70 mg/dL) after initial CHO intake. RESULTS When comparing the &amp;lt;70 (control) with the ≤80 and ≤90 mg/dL treatment groups, 100 vs. 86 (P = 0.1201) vs. 34% (P &amp;lt; 0.0001) of participants reached hypoglycemia, respectively. These hypoglycemic events lasted 26.0 ± 12.6 vs. 17.9 ± 14.7 (P = 0.026) vs. 7.1 ± 11.8 min (P = 0.002), with a PG nadir of 56.57 ± 9.91 vs. 63.60 ± 7.93 (P = 0.008) vs. 73.51 ± 9.37 mg/dL (P = 0.002), respectively. In the control group, 69% of participants required more than one treatment to reach or maintain normoglycemia (≥70 mg/dL), compared with 52% in the ≤80 mg/dL group and 31% in the ≤90 mg/dL group, with no significant rebound hyperglycemia (&amp;gt;180 mg/dL) within the first hour. CONCLUSIONS For some impending NS hypoglycemia episodes, individuals with TID could benefit from CHO intake at a higher BG level.
A temporal extracellular transcriptome atlas of human pre-implantation development
Authors: Qiuyang Wu, Zixu Zhou, Zhangming Yan, Megan Connel, Gabriel Garzo, Analisa Yeo, Wei Zhang, H. Irene Su, Sheng Zhong
Journal: Cell Genomics (2024)

Non-invasively evaluating gene expression products in human pre-implantation embryos remains a significant challenge. Here, we develop a non-invasive method for comprehensive characterization of the extracellular RNAs (exRNAs) in a single droplet of spent media that was used to culture human in vitro fertilization embryos. We generate the temporal extracellular transcriptome atlas (TETA) of human pre-implantation development. TETA consists of 245 exRNA sequencing datasets for five developmental stages. These data reveal approximately 4,000 exRNAs at each stage. The exRNAs of the developmentally arrested embryos are enriched with the genes involved in negative regulation of the cell cycle, revealing an exRNA signature of developmental arrest. Furthermore, a machine-learning model can approximate the morphology-based rating of embryo quality based on the exRNA levels. These data reveal the widespread presence of coding gene-derived exRNAs at every stage of human pre-implantation development, and these exRNAs provide rich information on the physiology of the embryo.
Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population
Authors: Kun Zhao, Xuxiang Shen, Hongwei Liu, Zhennan Lin, Jianxin Li, Shufeng Chen, Fangchao Liu, Keyong Huang, Jie Cao, Xiaoqing Liu, Chong Shen, Ling Yu, Yingxin Zhao, Liancheng Zhao, Ying Li, Dongsheng Hu, Jiangfeng Huang, Xiangfeng Lu, Dongfeng Gu
Journal: JAMA Cardiology (2024)

The genetic basis of coronary heart disease (CHD) has expanded from a germline to somatic genome, including clonal hematopoiesis of indeterminate potential (CHIP). How CHIP confers CHD risk in East Asian individuals, especially those with small clones (variant allele fraction [VAF] 0.5%-2%) and different genetic backgrounds, was completely unknown.
Erratum: “Systematic Evidence Map for over One Hundred and Fifty Per- and Polyfluoroalkyl Substances (PFAS)”
Authors: Laura M. Carlson, Michelle Angrish, Avanti V. Shirke, Elizabeth G. Radke, Brittany Schulz, Andrew Kraft, Richard Judson, Grace Patlewicz, Robyn Blain, Cynthia Lin, Nicole Vetter, Courtney Lemeris, Pamela Hartman, Heidi Hubbard, Xabier Arzuaga, Allen Davis, Laura V. Dishaw, Ingrid L. Druwe, Hillary Hollinger, Ryan Jones, J. Phillip Kaiser, Lucina Lizarraga, Pamela D. Noyes, Michele Taylor, Andrew J. Shapiro, Antony J. Williams, Kristina A. Thayer
Journal: Environmental Health Perspectives (2024)
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Authors: Angelo Armandi, Tiziana Sanavia, Ramy Younes, Gian Paolo Caviglia, Chiara Rosso, Olivier Govaere, Antonio Liguori, Paolo Francione, Rocìo Gallego-Duràn, Javier Ampuero, Grazia Pennisi, Rocio Aller, Dina Tiniakos, Alastair Burt, Ezio David, Fabio Vecchio, Marco Maggioni, Daniela Cabibi, Duncan McLeod, Maria Jesus Pareja, Marco Y W Zaki, Antonio Grieco, Per Stål, Stergios Kechagias, Anna Ludovica Fracanzani, Luca Valenti, Luca Miele, Piero Fariselli, Mohammed Eslam, Salvatore Petta, Hannes Hagström, Jacob George, Jörn M Schattenberg, Manuel Romero-Gómez, Quentin Mark Anstee, Elisabetta Bugianesi
Journal: Gut (2024)

Objective Hyperferritinaemia is associated with liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed the role of serum ferritin in predicting long-term outcomes or death. Design We evaluated the relationship between baseline serum ferritin and longitudinal events in a multicentre cohort of 1342 patients. Four survival models considering ferritin with confounders or non-invasive scoring systems were applied with repeated five-fold cross-validation schema. Prediction performance was evaluated in terms of Harrell’s C-index and its improvement by including ferritin as a covariate. Results Median follow-up time was 96 months. Liver-related events occurred in 7.7%, hepatocellular carcinoma in 1.9%, cardiovascular events in 10.9%, extrahepatic cancers in 8.3% and all-cause mortality in 5.8%. Hyperferritinaemia was associated with a 50% increased risk of liver-related events and 27% of all-cause mortality. A stepwise increase in baseline ferritin thresholds was associated with a statistical increase in C-index, ranging between 0.02 (lasso-penalised Cox regression) and 0.03 (ridge-penalised Cox regression); the risk of developing liver-related events mainly increased from threshold 215.5 µg/L (median HR=1.71 and C-index=0.71) and the risk of overall mortality from threshold 272 µg/L (median HR=1.49 and C-index=0.70). The inclusion of serum ferritin thresholds (215.5 µg/L and 272 µg/L) in predictive models increased the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score in the longitudinal risk assessment of liver-related events (C-indices&gt;0.71) and overall mortality (C-indices&gt;0.65). Conclusions This study supports the potential use of serum ferritin values for predicting the long-term prognosis of patients with MASLD.